Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Cheng, 2016, The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics, J. Thorac. Oncol., 11, 1653, 10.1016/j.jtho.2016.05.021 Oser, 2015, Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin, Lancet Oncol., 16, e165, 10.1016/S1470-2045(14)71180-5 Planchard, 2018, Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv192, 10.1093/annonc/mdy275 Noone, 1975, 1975 Bristol-Myers Squibb, 2019 European Medicines Agency, 2019 ONO Pharmaceutical, 2015 Bristol-Myers Squibb, 2018 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Reck, 2018, Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study, J. Thorac. Oncol., 13, 194, 10.1016/j.jtho.2017.10.029 Horn, 2015, 4170 Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs), Ann. Oncol., 26, ix125, 10.1093/annonc/mdv532.01 Horn, 2017, Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057), J. Clin. Oncol., 35, 3924, 10.1200/JCO.2017.74.3062 Vokes, 2018, Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases, Ann. Oncol., 29, 959, 10.1093/annonc/mdy041 Antonia, 2019, Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis, Lancet Oncol., 20, 1395, 10.1016/S1470-2045(19)30407-3 Sekine, 2008, Emerging ethnic differences in lung cancer therapy, Br. J. Cancer, 99, 1757, 10.1038/sj.bjc.6604721 Zhou, 2011, East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians, Chin. J. Cancer, 30, 287, 10.5732/cjc.011.10106 Soo, 2011, Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials, J. Thorac. Oncol., 6, 1030, 10.1097/JTO.0b013e3182199c03 Wu, 2019, Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial, J. Thorac. Oncol., 14, 867, 10.1016/j.jtho.2019.01.006 Lu, 2019, Retrospect and prospect for lung cancer in China: clinical advances of immune checkpoint inhibitors, Oncologist, 24, S21, 10.1634/theoncologist.2019-IO-S1-s02 Nishio, 2019, KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer, Cancer Sci., 110, 1012, 10.1111/cas.13932 Hida, 2018, Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study, Clin. Lung Cancer, 19, e405, 10.1016/j.cllc.2018.01.004 Borghaei, 2016, Nivolumab vs docetaxel in patients with advanced NSCLC: CheckMate 017/057 2-year update and exploratory cytokine profile analyses, 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Wu, 2018, CheckMate 078: patient-reported outcomes (PROs) with nivolumab vs docetaxel in advanced non-small cell lung cancer (NSCLC), J. Thorac. Oncol., 13, S1047, 10.1016/j.jtho.2018.10.020 Herbst, 2018, Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro, Ann. Oncol., 29 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Wu, 2019, Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS, Ann. Oncol., 30, 171, 10.1093/annonc/mdy554